Baxter International Inc (NYSE:BAX) Director Carole J. Shapazian sold 4,990 shares of Baxter International stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $66.05, for a total value of $329,589.50. The sale was disclosed in a filing with the SEC, which is available at this link.
Baxter International Inc (BAX) traded down $0.73 during trading on Wednesday, hitting $67.36. The company had a trading volume of 1,676,804 shares, compared to its average volume of 3,295,694. The stock has a market cap of $36,999.51, a P/E ratio of 52.12, a P/E/G ratio of 1.97 and a beta of 0.82. Baxter International Inc has a 52 week low of $51.03 and a 52 week high of $72.58. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.57 and a quick ratio of 2.05.
Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.05. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.77 billion. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 EPS. research analysts predict that Baxter International Inc will post 2.78 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 2nd. Stockholders of record on Friday, March 2nd will be issued a dividend of $0.16 per share. The ex-dividend date is Thursday, March 1st. This represents a $0.64 annualized dividend and a dividend yield of 0.95%. Baxter International’s payout ratio is 49.61%.
Baxter International declared that its board has authorized a stock repurchase plan on Tuesday, February 20th that permits the company to buyback $1.50 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Family Capital Trust Co bought a new position in shares of Baxter International during the 4th quarter valued at $103,000. Robecosam AG bought a new position in Baxter International in the 4th quarter worth $103,000. Community Bank N.A. raised its holdings in Baxter International by 152.7% in the 4th quarter. Community Bank N.A. now owns 1,655 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 1,000 shares during the period. Trustcore Financial Services LLC bought a new position in Baxter International in the 4th quarter worth $131,000. Finally, Grove Bank & Trust raised its holdings in Baxter International by 526.0% in the 3rd quarter. Grove Bank & Trust now owns 2,285 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,920 shares during the period. 85.56% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have issued reports on BAX shares. Deutsche Bank raised Baxter International from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Tuesday, February 20th. Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Zacks Investment Research cut Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Royal Bank of Canada restated a “hold” rating and set a $66.00 target price on shares of Baxter International in a research report on Wednesday, November 22nd. Finally, ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Baxter International presently has an average rating of “Buy” and an average price target of $71.00.
COPYRIGHT VIOLATION WARNING: This piece was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/03/14/carole-j-shapazian-sells-4990-shares-of-baxter-international-inc-bax-stock.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.